| Old Articles: <Older 6191-6200 Newer> |
 |
The Motley Fool February 12, 2010 Brian Orelli |
Too Bad It's Not in the "Restructuring" Business Shares of Boston Scientific slipped nearly 10% yesterday, after the company released earnings and guidance for this year.  |
The Motley Fool February 12, 2010 Rich Smith |
This Just In: Upgrades and Downgrades Initiating coverage on the Chinese medical device baker, Deutsche called Mindray "the leader in many of its product areas and a low-cost producer of medical equipment."  |
BusinessWeek February 11, 2010 Nussbaum & Tirrell |
Health Reform Is Dead. Let's Go Shopping Thriving insurers and hospital chains may start to gobble up competitors weakened by the recession.  |
The Motley Fool February 11, 2010 Brian Orelli |
A Wonder Drug With Not-So-Wonderful Side Effects Wonder drug or not, Isis Pharmaceuticals and Genzyme's cholesterol drug mipomersen's sales will be limited by side effects.  |
The Motley Fool February 11, 2010 Brian Orelli |
A Turnaround Year, But Not in a Good Way 2009 was a solid year for sanofi-aventis thanks to a boost from sales of swine flu vaccine and some help from the exchange rate. But 2010? Not so solid.  |
The Motley Fool February 11, 2010 Rich Smith |
American Science Takes Its Lumps Once again, AS&E suffers from lumpy earnings.  |
The Motley Fool February 11, 2010 Brian Orelli |
Blockbuster in Hand, It's Time to Show a Profit Elan predicts an operating profit for the first time in nine years.  |
The Motley Fool February 10, 2010 Brian Orelli |
Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause.  |
The Motley Fool February 9, 2010 Brian Orelli |
What Bipartisan Health-Care Reform Means for Investors Republicans and Democrats will debate on TV, but little may come of it.  |
The Motley Fool February 9, 2010 Brian Orelli |
Pfizer's Slippery Slope Discount cards for drugs help Pfizer track patients' use.  |
| <Older 6191-6200 Newer> Return to current articles. |